Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Albendazole in Asymptomatic Subarachnoid Neurocysticercosis
NCT03950037Phase 2Withdrawn
- Sponsor
- Oregon Health & Science University
- Start
- Jan 2022
- Primary completion
- Apr 2023
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of albendazole in neurocysticercosis (NCC), sponsored by Oregon Health & Science University. Primary endpoint: Serious Adverse Events at 3 months. Planned start Jan 2022; status: withdrawn.
02
Drugs
albendazole
03
Conditions
neurocysticercosis (NCC)
Beyond the preview
Go deeper on NCT03950037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03950037.